Trial
NCT03075527
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
AstraZeneca
Condition
Mesothelioma
Intervention
Tremelimumab
Why stopped
Criteria not met for second stage at time of interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-08